Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
Brief Summary: The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: hepatitis A inactivated virus vaccine | Intervention Type: BIOLOGICAL; Name: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: hepatitis A inactivated virus vaccine; Assigned to Arm(s): Havrix Group
B: Arm Label: Girls 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Boys 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls and Boys 9 to 14 Years V503 at Months 0 and 12; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls 9 to 14 Years V503 at Months 0, 2, and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Young Women 16 to 26 Years V503 at Months 0, 2, and 6; Type: ACTIVE_COMPARATOR; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Intervention Type: BIOLOGICAL; Name: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine); Assigned to Arm(s): Boys 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0, 2, and 6, Girls and Boys 9 to 14 Years V503 at Months 0 and 12, Young Women 16 to 26 Years V503 at Months 0, 2, and 6
C: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group
D: Arm Label: HPV Vaccine; Type: N/A; Interventions: N/A

Answer: D